The FDA has approved verteporfin for injection (Visudyne, QLT Photo Therapeutics, Vancouver, BC, and CIBA Vision, Duluth, Ga) for the treatment of age-related macular degeneration in patients with predominantly classic subfoveal choroidal neovascularization (CNV). The treatment is a two-stage process requiring administration of verteporfin for injection followed by light at a wavelength of/689±3nm from a nonthermal diode laser. Light activation of verteporfin in the plasma results in local damage to neovascular endothelium and consequent vessel occlusion.
Henney JE. New Therapy for Macular Degeneration. JAMA. 2000;283(21):2779. doi:10.1001/jama.283.21.2779-JFD00004-2-1
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: